FIG 8.

Complement factors C3a and C5a are not responsible for SARS-CoV-2 patient plasma-induced permeability increase. HLMVEC monolayers on ECIS plates were treated either with plasma from the normal patient or plasma from SARS-CoV-2 patients 005 or 008, C3a (A) or C5a (B) with or without the C3a or C5a receptor antagonist (C3aRA, SB290157 100 nM or C5aRA W54011, 100 nM). TER was measured continuously for 20 h. Bar graphs represent the selected time points for statistical analysis to compare each treatment group at 2 h after SARS-CoV-2 plasma treatment. Results are expressed as mean ± SEM of 3 independent experiments, n = 3. ****, P < 0.0001 versus normal plasma; ***, P < 0.001 versus normal plasma; **, P < 0.01 C3a versus C3aRA; *, P < 0.01 C5a versus C5aRA; ns, SARS-CoV-2 versus SARS-CoV-2 C3aRA or C5Ara. The statistical significance was assessed by one‐way ANOVA followed by Tukey’s multiple comparisons post hoc test using Graph Pad Prism.